MedTrace Logo

The Effect Of Lersivirine (UK-453,061) On Qt Intervals In Healthy Subjects

NCT00936871 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2010-09-06

No results posted yet for this study

Summary

This study has been designed to investigate the effect of lersivirine on the QT/QTc interval in order to help establish the safety profile of lersivirine.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Lersivirine

Lersivirine 2400 mg single dose

DRUG

Placebo

Placebo single dose

DRUG

Lersivirine (if necessary)

Lersivirine 2100 mg single dose (if necessary)

DRUG

Lersivirine

Lersivirine 2400 mg single dose (dose may be decreased pending Part A tolerability results)

DRUG

Placebo

Placebo single dose

DRUG

Moxifloxacin

Moxifloxacin 400 mg single dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00936871 on ClinicalTrials.gov